|Master Investor Magazine
Never miss an issue of Master Investor Magazine – sign-up now for free!
AIM-listed life sciences specialist ABCAM (LON:ABC) has seen its share price climb by 1.33% to 1,370p (as of 15:15 GMT) as it completed the acquisition of Expedeon’s subsidiaries, which was announced in November.
CEO Alan Hirzel commented: “We are delighted to have completed this transaction and welcome our new colleagues to Abcam. Expedeon’s portfolio of products and technology, combined with Abcam’s antibody and protein strengths, place us well to address the growing need for antibody conjugation and multiplexing solutions“.
The Master Investor Show 2020 tickets are now available. Join us at the Business Design Centre on Saturday 28 March 2020.
Book your FREE tickets today using code: MIBLOG